PALO ALTO, Calif.–(BUSINESS WIRE)–Endpoint Health, a precision-first therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses, today announced the appointment of several strategic advisors. These renowned industry leaders will provide counsel on the company’s efforts to advance precision therapeutics for immune-driven illnesses. Endpoint Health combines therapeutics, therapy guiding tests and artificial intelligence (AI) to develop targeted therapies for patients with diseases like acute respiratory distress syndrome (ARDS), sepsis and rheumatoid arthritis.
“We are pleased to welcome these distinguished leaders as strategic advisors to Endpoint Health,” said Jason Springs, co-founder and Chief Executive Officer at Endpoint Health. “Their deep expertise across discovery, development and commercialization of therapeutics and therapy guiding tests will be valuable to provide strategic counsel to the company as we move forward to develop personalized therapies for immune-driven critical and chronic illnesses with high unmet need.”
Individuals who will be joining Endpoint Health as strategic advisors include:
- Paul Brown, PhD, former Global Head of Roche Molecular Solutions. At Roche, Dr. Brown was responsible for overseeing the Company’s Molecular Diagnostics, Tissue Diagnostics and Sequencing Solutions Business Units globally. Prior to this position, Dr. Brown was President and Chief Executive Officer of Roche Molecular Diagnostics where he substantially grew its core businesses of virology, blood screening and infectious diseases, while improving the medical value and increasing the testing efficiency of products in development in the diagnostic areas of microbiology, oncology and genomics. Starting his career at Roche in 1986, Dr. Brown also held several leadership roles within the pharmaceutical division, including General Manager of Sweden, Vice President of Sales and Marketing in Canada, and Lifecycle Leader for Tamiflu® and Xenical®.
- Javier San Martin, MD, Chief Medical Officer of Arrowhead Pharmaceuticals. Dr. San Martin is responsible for guiding the Company’s research and development teams to help advance its growing pipeline of RNAi therapeutics leveraging the TRiM™ platform to target liver, lung, tumor, muscle and additional extra-hepatic tissues. Earlier in his career, Dr. San Martin served as Senior Vice President and Head of Global Clinical Development at Ultragenyx where he led the development of burosumab. Dr. San Martin also served as Senior Vice President of Clinical Development at Alder Biopharmaceuticals where he was responsible for managing the medical, regulatory and clinical operations group focused on early clinical programs. He also spent time at Amgen and Eli Lilly where he led numerous development and medical affairs activities.
- Merdad Parsey, MD, Chief Medical Officer of Gilead. Dr. Parsey spearheads Gilead’s global clinical development and medical affairs organizations, including the supervision of all clinical trials and development operations. Prior to Gilead, he served as Senior Vice President of Early Clinical Development at Genentech. Earlier in his career, Dr. Parsey served as President and CEO of 3-V Biosciences (now Sagimet BioSciences), held development roles at Sepracor, Regeneron and Merck, and was Assistant Professor of Medicine and Director of Critical Care Medicine at the New York University School of Medicine.
- Mike Varney, PhD, former head of Genentech’s Research and Early Development and a member of the Roche Executive Committee. Dr. Varney was recruited to Genentech to build its small molecule discovery capability, which now accounts for more than 40 percent of the company’s development portfolio, including the marketed anticancer agents Erivedge® and Cotellic®. Earlier in his career, Dr. Varney pioneered structure-based drug design as a founding employee at Agouron, which delivered Viracept® and resulted in the discovery of several currently marketed anticancer agents, including Xalkori® and Inlyta®. In 2018, Dr. Varney was also named Hero of Chemistry in 2018 by the American Chemical Society.
About Endpoint Health
Endpoint Health is a precision-first therapeutics company dedicated to addressing urgent needs in immune-driven critical and chronic illnesses by delivering therapies that are personalized to each patient’s biology. We combine therapeutics, therapy guiding tests and AI to develop targeted therapies for patients with inflammatory illnesses, such as acute respiratory distress syndrome (ARDS), sepsis and rheumatoid arthritis. Our vision is a world in which all patients have effective, personalized treatment, because therapies are targeted to the right patient at the right time. For more information, visit www.endpoint.health
Follow us on Social Media: LinkedIn, Twitter
Contacts
Christian Pflaumer
Ruder Finn
917.841.4525
Christian.Pflaumer@ruderfinn.com